Advanced Life Sciences Names New Chief Financial Officer
Richard Wieland, assumes role of EVP and CFO


Woodridge, Ill, Aug.10, 2004 - R. Richard Wieland, II, has assumed the duties of executive vice president and chief financial officer of Advanced Life Sciences (ALS), announced Michael T. Flavin, ALS chairman and chief executive officer.

“ We are very pleased to have Rich Wieland on our team,” said Flavin. “He has a very rich and deep pool of experience with emerging biotechnology firms. He has worked with our management team in the past and we believe that he is the right person to help guide our company through the next phases of development.”

Prior to joining Advanced Life Sciences, Wieland served as executive vice president and chief financial officer of MediChem Life Sciences where he was responsible for overseeing financial operations of MediChem and its subsidiaries.

He also assisted in the acquisitions ThermoGen and Emerald Biostructures and in completing MediChem’s initial public offering.

Wieland also spent eight years as senior vice president and chief financial officer of LyphoMed (a $200 million NASDAQ-traded generic pharmaceutical company) prior to its acquisition by Fujisawa Pharmaceutical Co. Ltd. in Osaka, Japan. Earlier in his career, Wieland served in the financial management program at Proctor And Gamble. He earned his Masters in Business Administration from Washington University in Saint Louis and his Bachelor of Arts degree in accounting and economics at Monmouth College in Monmouth, Ill.

Advanced Life Sciences is a privately held biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation using its platform in natural products and chemical proteomics coupled with expertise in drug development. (